Novartis investigating death possibly linked to Gilenya

Gilenya, or Fingolimod, is the first approved oral disease modifying drug for MS.

Novartis investigating death possibly linked to Gilenya

Postby MSUK » Tue Dec 13, 2011 12:27 am


One year after Novartis won FDA approval for a new type of drug to treat relapsing forms of multiple sclerosis and delay the progression of physical disabilities, the drugmaker is now investigating a death tied to its pill, which is called Gilenya. The disclosure, which was made by a Wall Street analyst, has the potential to cast a pall over a drug that has been expected to generate blockbuster sales.

Specifically, this is the first death of a patient within 24 hours of taking a first dose. For now, an exact cause of death has not been disclosed, and the drugmaker suggests that it remains unclear whether its pill was the reason.

However, in an investor note, Sanford Bernstein analyst Tim Anderson write that, “to us, it seems likely the company has a reasonable idea of the cause of death given the fact that this occurred about 20 days ago.”... Read More - ... ageid/1309
User avatar
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 3:00 pm


Return to Gilenya


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service